

DAFTAR PUSTAKA

- Agaba, D. C., Migisha, R., Namayanja, R., Katamba, G., Lugobe, H. M., Aheisibwe, H., Twesigomwe, G., & Ashaba, S. (2019). Prevalence and Associated Factors of Metabolic Syndrome among Patients with Severe Mental Illness Attending a Tertiary Hospital in Southwest Uganda. *BioMed Research International*, 2019, e1096201. <https://doi.org/10.1155/2019/1096201>
- American Psychiatric Association (Ed.). (2013). *Diagnostic and statistical manual of mental disorders: DSM-5* (5 ed.). American Psychiatric Association. 102.
- Arania, R., Triwahyuni, T., Esfandiari, F., & Nugraha, F. R. (2021). Hubungan antara Usia, Jenis Kelamin dan Tingkat Pendidikan dengan Kejadian Diabetes Mellitus di Klinik Mardi Waluyo Lampung Tengah. *Jurnal Medika Malahayati*, 5(3), 146–153. <https://doi.org/10.33024/jmm.v5i3.4200>
- Aronson, J. K. (Ed.). (2016). *Meyler's side effects of drugs: The international encyclopedia of adverse drug reactions and interactions* (16 ed.). Elsevier. 443–447.
- Aryani, F., & Sari, O. (2015). Gambaran Pola Penggunaan Antipsikotik pada Pasien Skizofrenia di Ruang Rawat Inap Rumah Sakit Jiwa. *Journal of Management and Pharmacy Practice*, 6(1), 35–40. <https://doi.org/10.22146/jmpf.236>
- Barbosa, M., & Fernandes, V. (2021). Rapid-onset clozapine-induced hyperglycemia: Pathways of glycaemic dysregulation. *BMJ Case Reports*, 14(9), e243938. <https://doi.org/10.1136/bcr-2021-243938>
- Chisholm-Burns, M. A., Schwinghammer, T. L., Wells, B. G., Malone, P. M., Kolesar, J. M., & DiPiro, J. T. (2016). *Pharmacotherapy Principles and Practice* (4 ed.). McGraw-Hill Education. 651–678.
- Chokhawala, K., & Stevens, L. (2021). Antipsychotic Medications. Dalam *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK519503/>
- Darsana, I. W., & Suariyani, N. L. P. (2020). Trend Karakteristik Pasien Skizofrenia di Rumah Sakit Rawat Jiwa Provinsi Bali (2013–2018). *Archive of Community Health*, 7(1), 41–51. <https://doi.org/10.24843/ACH.2020.v07.i01.p05>
- De Berardis, D., Rapini, G., Olivieri, L., Di Nicola, D., Tomasetti, C., Valchera, A., Fornaro, M., Di Fabio, F., Perna, G., Di Nicola, M., Serafini, G., Carano, A., Pompili, M., Vellante, F., Orsolini, L., Martinotti, G., & Di Giannantonio, M. (2018). Safety of antipsychotics for the treatment of schizophrenia: A focus on the adverse effects of clozapine. *Therapeutic Advances in Drug Safety*, 9(5), 237–256. <https://doi.org/10.1177/2042098618756261>
- Dinan, T. G. (2004). Stress and the genesis of diabetes mellitus in schizophrenia. *The British Journal of Psychiatry*, 184(S47), s72–s75. <https://doi.org/10.1192/bjp.184.47.s72>
- Farizah, N. A., Fitriany, E., & Nugrahayu, E. Y. (2020). Hubungan Fungsi Sosial dengan Kualitas Hidup Pasien Skizofrenia Rawat Jalan di Rumah Sakit Jiwa

- Daerah Atma Husada Mahakam Samarinda. *Motiva: Jurnal Psikologi*, 2(2), 43–50. <https://doi.org/10.31293/mv.v2i2.4436>
- Gianfrancesco, F. D., Grogg, A. L., Mahmoud, R. A., Wang, R., & Nasrallah, H. A. (2002). Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: Findings from a large health plan database. *The Journal of Clinical Psychiatry*, 63(10), 920–930. <https://doi.org/10.4088/jcp.v63n1010>
- Gogos, A., Sbisa, A. M., Sun, J., Gibbons, A., Udawela, M., & Dean, B. (2015). A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings. *International Journal of Endocrinology*, 2015, 615356. <https://doi.org/10.1155/2015/615356>
- Gunawan, S., & Rahmawati, R. (2021). Hubungan Usia, Jenis Kelamin dan Hipertensi dengan Kejadian Diabetes Mellitus Tipe 2 di Puskesmas Tugu Kecamatan Cimanggis Kota Depok Tahun 2019: *Arkesmas: Arsip Kesehatan Masyarakat*, 6(1), 15–22. <https://doi.org/10.22236/arkesmas.v6i1.5829>
- Haidary, H. A., & Padhy, R. K. (2021). Clozapine. Dalam *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK535399/>
- Hanief, N., & Noor, N. (2021). Gambaran Penggunaan Obat Antipsikotik Pada Pasien Skizofrenia di Rumah Sakit Jiwa Dr. Soeharto Heerdjan Periode Januari – Juni 2017. *Yarsi Journal of Pharmacology*, 2(1), 13–24.
- Henderson, D. C., Cagliero, E., Gray, C., Nasrallah, R. A., Hayden, D. L., Schoenfeld, D. A., & Goff, D. C. (2000). Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. *The American Journal of Psychiatry*, 157(6), 975–981. <https://doi.org/10.1176/appi.ajp.157.6.975>
- Holder, S. D., & Wayhs, A. (2014). Schizophrenia. *American Family Physician*, 90(11), 775–782.
- Holt, R. I. G. (2019). Association Between Antipsychotic Medication Use and Diabetes. *Current Diabetes Reports*, 19(10), 96. <https://doi.org/10.1007/s11892-019-1220-8>
- Ijaz, S., Bolea, B., Davies, S., Savović, J., Richards, A., Sullivan, S., & Moran, P. (2018). Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: A review of systematic reviews. *BMC Psychiatry*, 18(1), 275. <https://doi.org/10.1186/s12888-018-1848-y>
- Ikawati, Z. (2014). *Farmakoterapi Penyakit Sistem Syaraf Pusat*. Bursa Ilmu. 223-227.
- Ikawati, Z. (2018). *Tata Laksana Terapi Penyakit Sistem Syaraf Pusat (Pertama)*. Bursa Ilmu. 249-280.
- Irawan, D. (2010). *Prevalensi dan Faktor Risiko Kejadian Diabetes Melitus Tipe 2 di Daerah Urban Indonesia (Analisis Data Sekunder Riskesdas 2007)* [Universitas Indonesia]. <https://lib.ui.ac.id>
- Jentsch, J. D., & Roth, R. H. (1999). The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. *Neuropsychopharmacology: Official Publication of the*

- American College of Neuropsychopharmacology*, 20(3), 201–225.
[https://doi.org/10.1016/S0893-133X\(98\)00060-8](https://doi.org/10.1016/S0893-133X(98)00060-8)
- Josiassen, R. C., Joseph, A., Kohegyi, E., Stokes, S., Dadvand, M., Paing, W. W., & Shaughnessy, R. A. (2005). Clozapine augmented with risperidone in the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial. *The American Journal of Psychiatry*, 162(1), 130–136.
<https://doi.org/10.1176/appi.ajp.162.1.130>
- Kato, Y., Umetsu, R., Abe, J., Ueda, N., Nakayama, Y., Kinoshita, Y., & Nakamura, M. (2015). Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports. *Journal of Pharmaceutical Health Care and Sciences*, 1(1), 1–8.
<https://doi.org/10.1186/s40780-015-0015-6>
- Kavanagh, D. J. (1992). *Schizophrenia: An Overview And Practical Handbook*. Chapman & Hall. 374.
- Kelly, D. L., Weiner, E., & Wehring, H. J. (2016). Schizophrenia. Dalam *Pharmacotherapy: Principle and Practice* (Vol. 1–37, hlm. 563–580). McGraw-Hill Education.
- Kementerian Kesehatan RI. (2015). *Keputusan Menteri Kesehatan RI Nomor HK.02.02/MENKES/73/2015 tentang Pedoman Nasional Pelayanan Kedokteran Jiwa*. Kementerian Kesehatan RI. 24–25.
- Kementerian Kesehatan RI. (2018). *Riset Kesehatan Dasar 2018*. Kementerian Kesehatan RI. 225.
- Koller, E., Schneider, B., Bennett, K., & Dubitsky, G. (2001). Clozapine-associated diabetes. *The American Journal of Medicine*, 111(9), 716–723.
[https://doi.org/10.1016/s0002-9343\(01\)01000-2](https://doi.org/10.1016/s0002-9343(01)01000-2)
- Komariah, K., & Rahayu, S. (2020). Hubungan Usia, Jenis Kelamin dan Indeks Massa Tubuh dengan Kadar Gula Darah Puasa pada Pasien Diabetes Melitus Tipe 2 di Klinik Pratama Rawat Jalan Proklamasi, Depok, Jawa Barat. *Jurnal Kesehatan Kusuma Husada*, 41–50. <https://doi.org/10.34035/jk.v11i1.412>
- Kumar, P., Mishra, D. K., Mishra, N., Ahuja, S., Raghuvanshi, G., & Niranjana, V. (2019). Acute onset clozapine-induced hyperglycemia: A case report. *General Psychiatry*, 32(2), e100045. <https://doi.org/10.1136/gpsych-2018-100045>
- Lacy, C. F., Armstrong, L. L., Goldman, M. P., & Lance, L. L. (2009). *Drug Information Handbook* (17th edition). Lexi-Comp Inc.
- Lally, J., & MacCabe, J. H. (2015). Antipsychotic medication in schizophrenia: A review. *British Medical Bulletin*, 114(1), 169–179.
<https://doi.org/10.1093/bmb/ldv017>
- Lavretsky, H. (2008). History of Schizophrenia as a Psychiatric Disorder. Dalam *Clinical Handbook of Schizophrenia* (hlm. 3–12). Guilford Press.
- Liu, X., Wu, Z., Lian, J., Hu, C.-H., Huang, X.-F., & Deng, C. (2017). Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders

- associated with chronic clozapine or olanzapine treatment in rats. *Scientific Reports*, 7, 2762. <https://doi.org/10.1038/s41598-017-02884-w>
- Maslim, R. (2002). *Diagnosis Gangguan Jiwa, Rujukan Ringkas dari PPDGJ-III*. Bagian Ilmu Kedokteran Jiwa Fakultas Kedokteran Unika Atma Jaya. 48-51.
- McGrath, J., Saha, S., Chant, D., & Welham, J. (2008). Schizophrenia: A concise overview of incidence, prevalence, and mortality. *Epidemiologic Reviews*, 30, 67–76. <https://doi.org/10.1093/epirev/mxn001>
- Mordarska, K., & Godziejewska-Zawada, M. (2017). Diabetes in the elderly. *Przegląd Menopauzalny = Menopause Review*, 16(2), 38. <https://doi.org/10.5114/pm.2017.68589>
- Mouri, Mi., & Badireddy, M. (2022). Hyperglycemia. Dalam *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/books/NBK430900/>
- Muench, J., & Hamer, A. M. (2010). Adverse effects of antipsychotic medications. *American Family Physician*, 81(5), 617–622.
- Muliyani, M. M. (2019). Karakteristik Pasien Skizofrenia Rawat Jalan di Poli Jiwa RSUD. DR. H. MOCH. Ansari Saleh Banjarmasin. *Jurnal Kajian Ilmiah Kesehatan dan Teknologi*, 1(2), 21–25. <https://doi.org/10.52674/jkikt.v1i2.17>
- Novitayani, S. (2016). Karakteristik Pasien Skizofrenia dengan Riwayat Rehospitalisasi. *Idea Nursing Journal*, 7(3), 23–29. <https://doi.org/10.52199/inj.v7i3.6442>
- Nugroho, A. E. (2011). *Farmakologi: Obat-obat Penting dalam Pembelajaran Ilmu Farmasi dan Dunia Kesehatan*. Pustaka Pelajar. 68-69.
- Pahlawati, A., & Nugroho, P. S. (2019). Hubungan Tingkat Pendidikan dan Usia dengan Kejadian Diabetes Melitus di Wilayah Kerja Puskesmas Palaran Kota Samarinda Tahun 2019. *Borneo Student Research (BSR)*, 1(1), 1–5.
- Patel, K. R., Cherian, J., Gohil, K., & Atkinson, D. (2014). Schizophrenia: Overview and Treatment Options. *Pharmacy and Therapeutics*, 39(9), 638–645.
- Rini, S. (2015). Sindrom Metabolik. *J Majority*, 4(4), 88–93.
- Sadock, B. J., & Sadock, V. A. (2007). *Kaplan & Sadock's synopsis of psychiatry: Behavioral sciences/clinical psychiatry, 10th ed* (hlm. xv, 1470). Lippincott Williams & Wilkins Publishers. 1470.
- Sefrina, F. (2016). Hubungan Dukungan Keluarga dan Keberfungsian Sosial pada Pasien Skizofrenia Rawat Jalan. *Jurnal Ilmiah Psikologi Terapan*, 4(2), 140–160. <https://doi.org/10.22219/jipt.v4i2.3609>
- Stahl, S. M., Morrisette, D. A., Citrome, L., Saklad, S. R., Cummings, M. A., Meyer, J. M., O'Day, J. A., Dardashti, L. J., & Warburton, K. D. (2013). “Meta-guidelines” for the management of patients with schizophrenia. *CNS Spectrums*, 18(3), 150–162. <https://doi.org/10.1017/S109285291300014X>
- Stepnicki, P., Kondej, M., & Kaczor, A. A. (2018). Current Concepts and Treatments of Schizophrenia. *Molecules (Basel, Switzerland)*, 23(8), E2087. <https://doi.org/10.3390/molecules23082087>

- Suastika, K., Dwipayana, I. M., Saraswati, M., Kuswardhani, T., Astika, N., Putrawan, I., Matsumoto, K., Kajiwaru, N., & Taniguchi, H. (2011). Relationship between age and metabolic disorders in the population of Bali. *Hydrometallurgy*, 2, 47–52. <https://doi.org/10.1016/j.jcgg.2011.03.001>
- Suastika, K., Dwipayana, P., Semadi, M. S., & Kuswardhani, R. A. T. (2012). Age is an Important Risk Factor for Type 2 Diabetes Mellitus and Cardiovascular Diseases. *Intech Open*. <http://dx.doi.org/10.5772/52397>
- Sugiyono. (2013). *Metode Penelitian Kuantitatif, Kualitatif dan R&D*. Penerbit Alfabeta. 85.
- Tapp, A., Wood, A. E., Secrest, L., Erdmann, J., Cubberley, L., & Kilzieh, N. (2003). Combination Antipsychotic Therapy in Clinical Practice. *Psychiatric Services*, 54(1), 55–59. <https://doi.org/10.1176/appi.ps.54.1.55>
- Tovey, E., Rampes, H., & Livingstone, C. (2005). Clozapine-induced type-2 diabetes mellitus: Possible mechanisms and implications for clinical practice. *Journal of psychopharmacology (Oxford, England)*, 19, 207–210. <https://doi.org/10.1177/0269881105049043>
- Usman, J., Rahman, D., & Sulaiman, N. (2020). Faktor yang Berhubungan dengan Kejadian Diabetes Mellitus pada Pasien di RSUD Haji Makassar. *Jurnal Komunitas Kesehatan Masyarakat*, 2(1), 16–22.
- Ventriglio, A., Baldessarini, R. J., Vitrani, G., Bonfitto, I., Cecere, A. C., Rinaldi, A., Petito, A., & Bellomo, A. (2018). Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics. *Frontiers in Psychiatry*, 9, 744. <https://doi.org/10.3389/fpsy.2018.00744>
- Wang, P. S., Glynn, R. J., Ganz, D. A., Schneeweiss, S., Levin, R., & Avorn, J. (2002). Clozapine use and risk of diabetes mellitus. *Journal of Clinical Psychopharmacology*, 22(3), 236–243. <https://doi.org/10.1097/00004714-200206000-00002>
- WHO. (2019). *Schizophrenia*. <https://www.who.int/news-room/fact-sheets/detail/schizophrenia>
- Yuen, J. W. Y., Kim, D. D., Procyshyn, R. M., Panenka, W. J., Honer, W. G., & Barr, A. M. (2021). A Focused Review of the Metabolic Side-Effects of Clozapine. *Frontiers in Endocrinology*, 12, 67. <https://doi.org/10.3389/fendo.2021.609240>
- Yuen, J. W. Y., Wu, C., Wang, C. K., Kim, D. D., Procyshyn, R. M., Honer, W. G., & Barr, A. M. (2020). A comparison of the effects of clozapine and its metabolite norclozapine on metabolic dysregulation in rodent models. *Neuropharmacology*, 175, 107717. <https://doi.org/10.1016/j.neuropharm.2019.107717>
- Zahnia, S., & Sumekar, D. W. (2016). Kajian Epidemiologis Skizofrenia. *Jurnal Majority*, 5(4), 160–166.